Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
CompletedOBSERVATIONAL
Enrollment
2,662
Participants
Timeline
Start Date
July 31, 2003
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
Conditions
Crohn's Disease
Interventions
BIOLOGICAL
Remicade
The treating physician will determine the treatment regimen and dose of Remicade.
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00705614 - Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) | Biotech Hunter | Biotech Hunter